Details of the Drug

General Information of Drug (ID: DMKR3C5)

• Drug Name: Ergotamine
• Synonyms: Avetol; Cornutamin; Cornutamine; ETIN; Ergam; Ergate; Ergomar; Ergonsvine; Ergostat; Ergotamin; Ergotartrate; Exmigra; Femergin;Gynergen; Lingraine; Lingran; Migretamine; Rigetamin; Secagyn; Secupan; Temigran; Wigrettes; Ergotamine bitartrate; Ergotamine hemitartrate; Ergotamine tartrate; Gotamine tartrate; Medihaler ergotamine; Ergomar (TN); Ergotamina [INN-Spanish]; Ergotamine (INN); Ergotamine [INN:BAN]; Ergotamine tartrate (VAN); Ergotaminum [INN-Latin]; Ergoton-A; Neo-ergotin; Ergotamine, tartrate (2:1); Ergotamine tartrate, Avetol, Cornutamin, Ergam, Ergotartrate; ERGOTAMINE (SEE ALSO: ERGOTAMINE TARTRATE (CAS 379-79-3)); Ergotamine, tartrate (2:1) (salt) (8CI); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'-alpha)-(9CI); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt); (5'A)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman 2,3-dihydroxybutanedioate(2:1); 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione

Indication

Disease Entry	ICD 11	Status	REF
Cluster headache	8A81.0	Approved	[1]
Headache	8A80-8A84	Approved	[2]
Migraine disorder	N.A.	Approved	[1]

• Therapeutic Class: Analgesics
• Affected Organisms: Humans and other mammals
• ATC Code:
  N02CA02: Ergotamine
  N02CA: Ergot alkaloids
  N02C: ANTIMIGRAINE PREPARATIONS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
  N02CA02: Ergotamine
  N02CA: Ergot alkaloids
  N02C: ANTIMIGRAINE PREPARATIONS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
  N02CA02: Ergotamine
  N02CA: Ergot alkaloids
  N02C: ANTIMIGRAINE PREPARATIONS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
  N02CA02: Ergotamine
  N02CA: Ergot alkaloids
  N02C: ANTIMIGRAINE PREPARATIONS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
  N02CA02: Ergotamine
  N02CA: Ergot alkaloids
  N02C: ANTIMIGRAINE PREPARATIONS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 581.7
  Logarithm of the Partition Coefficient (xlogp); 2
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 6
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 15 mL/min/kg [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 2 hours [4]
  Metabolism: The drug is metabolized via the hepatic []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.1473 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.02% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.6 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 2 mg/mL [3]
• Chemical Identifiers:
  Formula: C33H35N5O5
  IUPAC Name: (6aR,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
  Canonical SMILES: C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C
  InChI: InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1
  InChIKey: XCGSFFUVFURLIX-VFGNJEKYSA-N
• Cross-matching ID:
  PubChem CID: 8223
  ChEBI ID: CHEBI:64318
  CAS Number: 379-79-3
  UNII: PR834Q503T
  DrugBank ID: DB00696
  TTD ID: D01TSI
  VARIDT ID: DR00500
  INTEDE ID: DR0600
  ACDINA ID: D00238
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor Alpha-1 (ADRA1)	TTG28O6	NOUNIPROTAC	Agonist	[6]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[9]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[10]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ergotamine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Ergotamine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[11]
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Ergotamine caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[12]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Ergotamine caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[12]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Ergotamine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[12]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Ergotamine caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[13]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Ergotamine caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[13]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Ergotamine caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[12]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Ergotamine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[13]
Ephedrine	DMMV0KW	Major	Additive hypertensive effects by the combination of Ergotamine and Ephedrine.	Asthma [CA23]	[14]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Ergotamine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Ergotamine caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[12]
Tucatinib	DMBESUA	Major	Decreased metabolism of Ergotamine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Ergotamine caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
Pseudoephedrine	DMIVJ0D	Major	Additive hypertensive effects by the combination of Ergotamine and Pseudoephedrine.	Breathing abnormality [MD11]	[14]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Ergotamine caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[12]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Ergotamine and Levomilnacipran.	Chronic pain [MG30]	[15]
Mifepristone	DMGZQEF	Major	Decreased metabolism of Ergotamine caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[16]
Pasireotide	DMHM7JS	Moderate	Decreased metabolism of Ergotamine caused by Pasireotide mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[13]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Ergotamine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[13]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Ergotamine caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[13]
MK-8228	DMOB58Q	Major	Decreased metabolism of Ergotamine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[13]
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Ergotamine and Sertraline.	Depression [6A70-6A7Z]	[15]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Ergotamine and Vilazodone.	Depression [6A70-6A7Z]	[15]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Ergotamine caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[13]
Paroxetine	DM5PVQE	Major	Additive serotonergic effects by the combination of Ergotamine and Paroxetine.	Depression [6A70-6A7Z]	[15]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Ergotamine and Selegiline.	Depression [6A70-6A7Z]	[11]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Ergotamine and Vortioxetine.	Depression [6A70-6A7Z]	[15]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Ergotamine and Isocarboxazid.	Depression [6A70-6A7Z]	[11]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Ergotamine and Milnacipran.	Depression [6A70-6A7Z]	[15]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Ergotamine and Escitalopram.	Depression [6A70-6A7Z]	[15]
Tranylcypromine	DMGB5RE	Major	Additive serotonergic effects by the combination of Ergotamine and Tranylcypromine.	Depression [6A70-6A7Z]	[11]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Ergotamine and Desvenlafaxine.	Depression [6A70-6A7Z]	[15]
Phenelzine	DMHIDUE	Major	Additive serotonergic effects by the combination of Ergotamine and Phenelzine.	Depression [6A70-6A7Z]	[11]
LEVONORDEFRIN	DMWDJ0H	Major	Additive hypertensive effects by the combination of Ergotamine and LEVONORDEFRIN.	Discovery agent [N.A.]	[14]
Primidone	DM0WX6I	Moderate	Increased metabolism of Ergotamine caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Ergotamine caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Ergotamine caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Ergotamine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Ergotamine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Ergotamine caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Ergotamine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Ergotamine caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Ergotamine caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Mephentermine	DMFJH5Q	Major	Additive hypertensive effects by the combination of Ergotamine and Mephentermine.	Essential hypertension [BA00]	[14]
Oxymetazoline	DM8ZXT6	Major	Additive hypertensive effects by the combination of Ergotamine and Oxymetazoline.	Eyelid inflammatory disorder [9A02]	[14]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Ergotamine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[12]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Ergotamine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[13]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Ergotamine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[13]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Ergotamine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[18]
Telaprevir	DMMRV29	Major	Decreased metabolism of Ergotamine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[18]
Tetrahydrozoline	DMT57WC	Major	Additive hypertensive effects by the combination of Ergotamine and Tetrahydrozoline.	Herpes simplex infection [1F00]	[14]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Ergotamine caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[13]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Ergotamine caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[12]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Ergotamine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[12]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Ergotamine and Procarbazine.	Hodgkin lymphoma [2B30]	[11]
MK-1439	DM215WE	Moderate	Increased metabolism of Ergotamine caused by MK-1439 mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Ergotamine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Ergotamine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Ergotamine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Saquinavir	DMG814N	Major	Decreased metabolism of Ergotamine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Ergotamine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Ergotamine caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Darunavir	DMN3GCH	Major	Decreased metabolism of Ergotamine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Ergotamine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
BMS-201038	DMQTAGO	Moderate	Decreased metabolism of Ergotamine caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[13]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Ergotamine caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[13]
Methoxamine	DMF5XQH	Major	Additive hypertensive effects by the combination of Ergotamine and Methoxamine.	Hypertension [BA00-BA04]	[14]
Conivaptan	DM1V329	Major	Decreased metabolism of Ergotamine caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[13]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Ergotamine caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[19]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Ergotamine caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[12]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Ergotamine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[13]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Ergotamine caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[13]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Ergotamine caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[12]
Naphazoline	DMJFZDL	Major	Additive hypertensive effects by the combination of Ergotamine and Naphazoline.	Itching [1F28-1G07]	[14]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Ergotamine caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[13]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Ergotamine caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[12]
Ceritinib	DMB920Z	Major	Decreased metabolism of Ergotamine caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[13]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Ergotamine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[20]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Ergotamine caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[21]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Ergotamine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[13]
Idelalisib	DM602WT	Major	Decreased metabolism of Ergotamine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[13]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Ergotamine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[13]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Ergotamine caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[12]
LGX818	DMNQXV8	Moderate	Increased metabolism of Ergotamine caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[22]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Ergotamine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[21]
Danazol	DML8KTN	Moderate	Decreased metabolism of Ergotamine caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[13]
Exjade	DMHPRWG	Moderate	Increased metabolism of Ergotamine caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[12]
Ozanimod	DMT6AM2	Moderate	Additive serotonergic effects by the combination of Ergotamine and Ozanimod.	Multiple sclerosis [8A40]	[11]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Ergotamine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[13]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Ergotamine caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[13]
Modafinil	DMYILBE	Moderate	Increased metabolism of Ergotamine caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[12]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Ergotamine caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[23]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Ergotamine caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[13]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Ergotamine and Sibutramine.	Obesity [5B80-5B81]	[24]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Ergotamine and Dexfenfluramine.	Obesity [5B80-5B81]	[15]
Propylhexedrine	DMTBW2O	Major	Additive hypertensive effects by the combination of Ergotamine and Propylhexedrine.	Obesity [5B80-5B81]	[14]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Ergotamine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[13]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Ergotamine and Safinamide.	Parkinsonism [8A00]	[11]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Ergotamine and Rasagiline.	Parkinsonism [8A00]	[11]
Dopamine	DMPGUCF	Major	Additive hypertensive effects by the combination of Ergotamine and Dopamine.	Parkinsonism [8A00]	[14]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Ergotamine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[25]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Ergotamine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[26]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Ergotamine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[13]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Ergotamine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[13]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Ergotamine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[12]
Bicalutamide	DMZMSPF	Moderate	Decreased metabolism of Ergotamine caused by Bicalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[13]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Ergotamine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[27]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Ergotamine caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[12]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Ergotamine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[13]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Ergotamine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[12]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Ergotamine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[13]
Armodafinil	DMGB035	Moderate	Increased metabolism of Ergotamine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[12]
LEE011	DMMX75K	Moderate	Decreased metabolism of Ergotamine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[13]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Ergotamine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[12]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Ergotamine due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[28]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Ergotamine and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[27]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Ergotamine and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[27]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Ergotamine caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[12]
Xylometazoline	DMKV32D	Major	Additive hypertensive effects by the combination of Ergotamine and Xylometazoline.	Vasomotor/allergic rhinitis [CA08]	[14]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Ergotamine caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[13]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 1	E00263	19700	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Saccharin sodium dihydrate	E00577	46942257	Flavoring agent
Crospovidone	E00626	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ergotamine 2 mg tablet	2 mg	Sublingual Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Ergotamine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 149).
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Reversal of ergotamine-induced vasospasm following methylprednisolone. Clin Toxicol (Phila). 2008 Dec;46(10):1074-6.
• [7] Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
• [8] Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9.
• [9] Frovatriptan: a review of drug-drug interactions. Headache. 2002 Apr;42 Suppl 2:S63-73.
• [10] Cytotoxicity and accumulation of ergot alkaloids in human primary cells. Toxicology. 2011 Apr 11;282(3):112-21. doi: 10.1016/j.tox.2011.01.019. Epub 2011 Feb 2.
• [11] Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
• [12] Cerner Multum, Inc. "Australian Product Information.".
• [13] Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
• [14] Barthel W, Glusa E, Koth W "Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ." Int J Clin Pharmacol Ther Toxicol 25 (1987): 63-9. [PMID: 2881898]
• [15] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
• [16] He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
• [17] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [18] Baldwin ZK, Ceraldi CC "Ergotism associated with HIV antiviral protease inhibitor therapy." J Vasc Surg 37 (2003): 676-8. [PMID: 12618710]
• [19] Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
• [20] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [21] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [22] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [23] Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
• [24] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
• [25] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [26] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [27] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [28] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.